Cargando…
Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma
INTRODUCTION: Upper urinary tract epithelial carcinoma (UTUC) and bladder cancer are both sources of urinary epithelial cell. In our previous study of asymptomatic bladder tumors, we found that most of these tumors could be resected through the urethra without radical surgery. This study analyzed th...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481439/ https://www.ncbi.nlm.nih.gov/pubmed/37680741 http://dx.doi.org/10.5114/wiitm.2022.123307 |
_version_ | 1785101974133276672 |
---|---|
author | Lin, Deng Hong, Yun Yang, Zesong Ye, Liefu |
author_facet | Lin, Deng Hong, Yun Yang, Zesong Ye, Liefu |
author_sort | Lin, Deng |
collection | PubMed |
description | INTRODUCTION: Upper urinary tract epithelial carcinoma (UTUC) and bladder cancer are both sources of urinary epithelial cell. In our previous study of asymptomatic bladder tumors, we found that most of these tumors could be resected through the urethra without radical surgery. This study analyzed the treatment strategies for asymptomatic UTUC. AIM: To investigate the clinicopathological features and surgical methods of these patients, thus choosing appropriate surgical treatment. MATERIAL AND METHODS: 136 patients with UTUC were recruited, of whom 21 patients with asymptomatic UTUC were group A, and 115 UTUC patients with hematuria or low back pain were group B. The clinicopathological features, oncologic outcomes, and surgical methods of patients were evaluated. RESULTS: Radical resection was the main surgical treatment which was included (group A 80.95%, group B 90.43%). Other patients were treated with kidney-retaining surgery. No statistically significant difference was observed in the pathological stage and grade between groups A and B (p > 0.05). During a median follow-up period of 44.3 months, tumor-specific mortality of group A was 7.14%, and that of group B was 5.10%. In the same period, 106 patients with asymptomatic bladder tumor were recruited: 31 patients of them had asymptomatic bladder urothelial carcinoma. The asymptomatic UTUC group had a higher stage and grade of clinicopathological features than the asymptomatic bladder urothelial carcinoma group (p < 0.001). CONCLUSIONS: The principle of asymptomatic UTUC treatment is the same as that of symptomatic UTUC. Risk stratification should be carried out according to clinical staging and other parameters, and the corresponding surgical treatment should be selected. |
format | Online Article Text |
id | pubmed-10481439 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-104814392023-09-07 Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma Lin, Deng Hong, Yun Yang, Zesong Ye, Liefu Wideochir Inne Tech Maloinwazyjne Original Paper INTRODUCTION: Upper urinary tract epithelial carcinoma (UTUC) and bladder cancer are both sources of urinary epithelial cell. In our previous study of asymptomatic bladder tumors, we found that most of these tumors could be resected through the urethra without radical surgery. This study analyzed the treatment strategies for asymptomatic UTUC. AIM: To investigate the clinicopathological features and surgical methods of these patients, thus choosing appropriate surgical treatment. MATERIAL AND METHODS: 136 patients with UTUC were recruited, of whom 21 patients with asymptomatic UTUC were group A, and 115 UTUC patients with hematuria or low back pain were group B. The clinicopathological features, oncologic outcomes, and surgical methods of patients were evaluated. RESULTS: Radical resection was the main surgical treatment which was included (group A 80.95%, group B 90.43%). Other patients were treated with kidney-retaining surgery. No statistically significant difference was observed in the pathological stage and grade between groups A and B (p > 0.05). During a median follow-up period of 44.3 months, tumor-specific mortality of group A was 7.14%, and that of group B was 5.10%. In the same period, 106 patients with asymptomatic bladder tumor were recruited: 31 patients of them had asymptomatic bladder urothelial carcinoma. The asymptomatic UTUC group had a higher stage and grade of clinicopathological features than the asymptomatic bladder urothelial carcinoma group (p < 0.001). CONCLUSIONS: The principle of asymptomatic UTUC treatment is the same as that of symptomatic UTUC. Risk stratification should be carried out according to clinical staging and other parameters, and the corresponding surgical treatment should be selected. Termedia Publishing House 2022-12-22 2023-06 /pmc/articles/PMC10481439/ /pubmed/37680741 http://dx.doi.org/10.5114/wiitm.2022.123307 Text en Copyright © 2023 Sekcja Wideochirurgii TChP https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) ) |
spellingShingle | Original Paper Lin, Deng Hong, Yun Yang, Zesong Ye, Liefu Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma |
title | Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma |
title_full | Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma |
title_fullStr | Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma |
title_full_unstemmed | Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma |
title_short | Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma |
title_sort | therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481439/ https://www.ncbi.nlm.nih.gov/pubmed/37680741 http://dx.doi.org/10.5114/wiitm.2022.123307 |
work_keys_str_mv | AT lindeng therapeuticstrategiesforasymptomaticupperurinarytracturothelialcarcinoma AT hongyun therapeuticstrategiesforasymptomaticupperurinarytracturothelialcarcinoma AT yangzesong therapeuticstrategiesforasymptomaticupperurinarytracturothelialcarcinoma AT yeliefu therapeuticstrategiesforasymptomaticupperurinarytracturothelialcarcinoma |